Jump to content

Erfonrilimab

From Wikipedia, the free encyclopedia
Erfonrilimab
Monoclonal antibody
TypeF(ab')2 fragment
TargetCTLA-4, PD-L1
Clinical data
Drug classAntineoplastic agent
ATC code
Identifiers
CAS Number
PubChem CID
UNII

Erfonrilimab is a investigational drug being evaluated for use in cancer immunotherapy.[1] It is a bispecific antibody targeting PD-L1 and CTLA-4.[2]

References

[edit]
  1. ^ "Erfonrilimab - Alphamab". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Xiong A, Li W, Li X, Fan Y, Ma Z, Fang J, et al. (September 2023). "Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study". European Journal of Cancer. 190: 112936. doi:10.1016/j.ejca.2023.05.024. PMID 37393762.